Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Rosenthal

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Oncotarget|December 22, 2016
Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancerStefan Kiechl, Daniel Schramek, Martin Widschwendter, et al.
Haematologica|June 22, 2019
Microhomology-mediated end joining drives complex rearrangements and overexpression of <i>MYC</i> and <i>PVT1</i> in multiple myelomaAneta Mikulasova, Cody Ashby, Ruslana G Tytarenko, et al.
Biorxiv : the Preprint Server for Biology|February 12, 2026
RNA Quality Control Enables Antibiotic ToleranceAndrew T Nishimoto, Juan C Ortiz-Marquez, Michelle R Scribner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2025
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2020
<i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple MyelomaEileen M Boyle, Cody Ashby, Ruslana G Tytarenko, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 29, 2019
The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndromeEmma J Crosbie, Neil A J Ryan, Mark J Arends, et al.
Plos Medicine|November 4, 2020
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trialsSamuel A Danziger, Mark McConnell, Jake Gockley, et al.
JCO Precision Oncology|August 11, 2022
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint InhibitorsDiana Merino Vega, Katherine K Nishimura, Névine Zariffa, et al.
Leukemia|July 4, 2018
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Blood|June 10, 2018
Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Oncotarget|December 22, 2016
Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancerStefan Kiechl, Daniel Schramek, Martin Widschwendter, et al.
Haematologica|June 22, 2019
Microhomology-mediated end joining drives complex rearrangements and overexpression of <i>MYC</i> and <i>PVT1</i> in multiple myelomaAneta Mikulasova, Cody Ashby, Ruslana G Tytarenko, et al.
Biorxiv : the Preprint Server for Biology|February 12, 2026
RNA Quality Control Enables Antibiotic ToleranceAndrew T Nishimoto, Juan C Ortiz-Marquez, Michelle R Scribner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2025
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2020
<i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple MyelomaEileen M Boyle, Cody Ashby, Ruslana G Tytarenko, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 29, 2019
The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndromeEmma J Crosbie, Neil A J Ryan, Mark J Arends, et al.
Plos Medicine|November 4, 2020
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trialsSamuel A Danziger, Mark McConnell, Jake Gockley, et al.
JCO Precision Oncology|August 11, 2022
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint InhibitorsDiana Merino Vega, Katherine K Nishimura, Névine Zariffa, et al.
Leukemia|July 4, 2018
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Blood|June 10, 2018
Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Pageof 6